Wegovy vs Zepbound 2026: Which FDA-Approved Weight Loss Drug Is Better?

2026 Quick Answer

Greater average weight loss: Zepbound (tirzepatide) — 20–22% vs 15–17% for Wegovy
Longer track record: Wegovy — FDA-approved June 2021 vs Zepbound November 2023
Cardiovascular outcomes data: Wegovy — SELECT trial showed 20% MACE reduction
Trend data: Zepbound surpassed Ozempic in US search volume in January 2026
Brand cost (no insurance): Both $1,000–$1,500/month
Compounded cost at Trimi: Semaglutide $99/mo · Tirzepatide $125/mo

The FDA-Approved Obesity Medications: Background

Both Wegovy and Zepbound represent a new class of obesity pharmacotherapy that has fundamentally changed what is medically possible for weight management. For decades, the only FDA-approved weight loss drugs offered modest 5–8% weight reduction. These two medications changed that ceiling dramatically.

Wegovy (semaglutide 2.4 mg injection) was approved by the FDA in June 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It is manufactured by Novo Nordisk — the same company that makes Ozempic (semaglutide for type 2 diabetes). Wegovy is the weight-loss branded version of the semaglutide molecule.

Zepbound (tirzepatide injection) was approved by the FDA in November 2023 for the same weight management indication. It is manufactured by Eli Lilly — the same company that makes Mounjaro (tirzepatide for type 2 diabetes). Zepbound is the weight-loss branded version of the tirzepatide molecule. In a remarkable sign of its ascent, Zepbound surpassed Ozempic in US search volume in January 2026, indicating it has become the most sought-after weight loss brand name in the country.

Both medications are prescription-only, require weekly subcutaneous self-injections, and are intended for long-term use as part of a comprehensive weight management program. Neither is a cure — discontinuation typically results in weight regain. Understanding the differences between these two medications is essential for any patient or provider making a treatment decision.

Drug Profiles: Wegovy and Zepbound

Wegovy (Semaglutide 2.4 mg)

Active Ingredient	Semaglutide
Mechanism	GLP-1 receptor agonist (single agonist)
Manufacturer	Novo Nordisk
FDA Approval Date	June 4, 2021
Approved For	Chronic weight management (BMI ≥30, or ≥27 with comorbidities)
Dosing Schedule	Once weekly subcutaneous injection; escalate to 2.4 mg over 16–20 weeks
Available Doses	0.25, 0.5, 1.0, 1.7, 2.4 mg
Delivery Device	Pre-filled FlexPen auto-injector
Brand List Price	~$1,349/month (no insurance)
Compounded at Trimi	$99/month

Zepbound (Tirzepatide)

Active Ingredient	Tirzepatide
Mechanism	Dual GIP/GLP-1 receptor agonist (dual agonist)
Manufacturer	Eli Lilly
FDA Approval Date	November 8, 2023
Approved For	Chronic weight management (BMI ≥30, or ≥27 with comorbidities)
Dosing Schedule	Once weekly subcutaneous injection; start at 2.5 mg, escalate to 10–15 mg
Available Doses	2.5, 5, 7.5, 10, 12.5, 15 mg
Delivery Device	Pre-filled auto-injector pen or single-dose vial
Brand List Price	~$1,060–$1,200/month (no insurance)
Compounded at Trimi	$125/month

How They Work: Mechanism Comparison

Understanding why these drugs produce different weight loss outcomes requires understanding their mechanisms. Both work primarily by slowing gastric emptying, suppressing appetite via the brain's hypothalamus, and improving insulin sensitivity — but tirzepatide adds a second mechanism that semaglutide lacks.

Semaglutide (Wegovy) is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone naturally released by the gut after eating. It signals the brain to reduce hunger, slows the movement of food from the stomach to the small intestine (increasing feelings of fullness), and stimulates insulin release in a glucose-dependent manner. Semaglutide mimics this hormone with approximately 94% structural homology to human GLP-1, but with modifications that extend its half-life to approximately one week — enabling once-weekly dosing.

Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 receptor (same mechanism as semaglutide) and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone involved in energy homeostasis and fat metabolism. The dual activation is believed to work synergistically — the GIP component may enhance the brain's response to GLP-1 signaling, amplify fat metabolism in adipose tissue, and improve the overall appetite-suppressing effect. This dual mechanism is widely credited with tirzepatide's superior weight loss outcomes in clinical trials.

Both drugs are structurally similar to natural gut hormones and have been engineered for once-weekly dosing. Both require subcutaneous injection. Neither causes weight loss through stimulant or diuretic mechanisms — the weight loss is genuine fat mass reduction driven by sustained caloric deficit from reduced appetite.

Clinical Results: STEP vs SURMOUNT Trials

Wegovy: The STEP Trial Program

Wegovy's FDA approval was supported by the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program. The pivotal STEP-1 trial enrolled 1,961 adults with obesity or overweight plus comorbidities (without diabetes) and randomized them to semaglutide 2.4 mg or placebo for 68 weeks.

Key STEP-1 results: average weight loss of 14.9% of body weight (approximately 33.7 lbs) with semaglutide vs 2.4% with placebo. 69.1% of participants on semaglutide achieved at least 10% weight loss, and 50.5% achieved at least 15% weight loss. These results were unprecedented for a non-surgical weight loss intervention at the time.

The SELECT trial (published in 2023) extended Wegovy's clinical profile by demonstrating a 20% reduction in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and obesity. This cardiovascular outcomes data is currently unique to semaglutide among weight loss medications — Zepbound does not yet have equivalent long-term cardiovascular outcomes trial results.

Zepbound: The SURMOUNT Trial Program

Zepbound's approval was supported by the SURMOUNT trial program. The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight plus comorbidities (without diabetes). Participants were randomized to tirzepatide 5, 10, or 15 mg weekly or placebo for 72 weeks.

SURMOUNT-1 results exceeded all prior weight loss drug trials: at the 15 mg dose, average weight loss was 20.9% of body weight (approximately 48 lbs). At 10 mg, weight loss averaged 19.5%. At 5 mg, 15.0%. Nearly 37% of patients on the highest dose achieved 25% or more body weight loss — a threshold previously only achievable with bariatric surgery.

The critical head-to-head trial is SURMOUNT-5, which directly compared tirzepatide 10 and 15 mg to semaglutide 2.4 mg in adults with obesity. Results showed tirzepatide produced average weight loss of 20.2% vs 13.7% with semaglutide — a statistically significant difference of 6.5 percentage points. Tirzepatide was superior to semaglutide on all pre-specified weight loss endpoints.

Clinical Results Comparison

Metric	Wegovy (STEP-1)	Zepbound (SURMOUNT-1)
Average weight loss	14.9%	20.9% (15 mg dose)
Average lbs lost	~33.7 lbs	~48 lbs
≥10% weight loss	69.1%	91.8%
≥15% weight loss	50.5%	81.4%
≥20% weight loss	32.0%	56.8%
≥25% weight loss	N/A	36.9%
Trial duration	68 weeks	72 weeks
CV outcomes data	Yes (SELECT trial)	Pending (SURMOUNT-MMO)
Head-to-head winner	—	Zepbound (SURMOUNT-5: 20.2% vs 13.7%)

Side Effect Profiles

Both Wegovy and Zepbound share the same core side effect profile because both work through the GLP-1 pathway. The most common adverse effects are gastrointestinal and occur primarily during dose escalation:

Nausea: 44% with Wegovy, 35–45% with Zepbound — typically peaks during dose increases and improves over time
Diarrhea: 30% with Wegovy, 23–30% with Zepbound
Vomiting: 24% with Wegovy, 11–25% with Zepbound
Constipation: 24% with Wegovy, 17–22% with Zepbound
Abdominal pain: Common to both during escalation
Fatigue: Reported with both, particularly early in treatment

Serious but less common risks apply to both: pancreatitis (rare), gallbladder disease, heart rate increase, and a theoretical risk of thyroid C-cell tumors (based on rodent data; not confirmed in humans, but both carry a black box warning). Neither drug should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).

The clinical trial dropout rates due to adverse events were similar: approximately 7–8% for Wegovy and 7–9% for Zepbound. Most patients tolerate both medications well, particularly at lower doses. The standard approach to managing GLP-1 side effects applies to both — slow titration, eating smaller meals, staying hydrated, and taking the injection at night can all help.

Important Safety Note

Both Wegovy and Zepbound carry a boxed warning regarding thyroid C-cell tumors based on rodent studies. Do not use either medication if you or a family member has had medullary thyroid carcinoma or MEN-2. Tell your provider about all other medications you take, as both can affect gastric motility and absorption of oral medications. Always follow the prescribed titration schedule — rushing dose escalation significantly increases side effect risk.

Insurance Coverage Comparison

Insurance coverage for obesity medications remains one of the most frustrating aspects of weight loss treatment in the United States. Despite FDA approval for both Wegovy and Zepbound, many patients face significant coverage barriers.

Wegovy Insurance Coverage

Covered by an increasing number of commercial insurance plans, but still widely excluded
Many plans require documented obesity with comorbidities, prior authorization, and failure of dietary interventions
Medicare does not cover Wegovy for weight loss only (coverage expanded if you also have established cardiovascular disease, per SELECT trial data — the TREAT Act could expand this)
Novo Nordisk's savings program can reduce costs for commercially insured eligible patients to as low as $25/month, but eligibility requirements apply
Government/VA plans generally do not cover Wegovy for weight management alone

Zepbound Insurance Coverage

Coverage is growing but still inconsistent — similar barriers to Wegovy
Eli Lilly launched a direct-to-consumer vial program at reduced pricing for cash-pay patients ($349–$549/month)
Manufacturer savings card for commercially insured eligible patients
Medicare coverage for Zepbound for weight loss only remains unavailable
Some plans cover it under broader obesity management coverage riders that employers may add

Coverage Trend

Coverage for GLP-1 obesity medications is expanding slowly. The TREAT Act, if passed, would require Medicare to cover obesity medications including Wegovy and Zepbound. Several large self-insured employers have added obesity drug coverage as a benefit. However, as of April 2026, the majority of Americans still lack adequate insurance coverage for either medication, making the cost comparison below critically important.

Cost Comparison: Brand vs Compounded

The cost of brand-name Wegovy and Zepbound puts long-term treatment out of reach for most uninsured or underinsured Americans. At $1,000–$1,500 per month, a year of treatment costs between $12,000 and $18,000. Compounded alternatives provide the same active ingredients at dramatically lower prices.

Option	Monthly Cost	Annual Cost	Notes
Brand Wegovy	~$1,349/mo	~$16,200/yr	No insurance; Novo Nordisk savings card may reduce if insured
Brand Zepbound (pen)	~$1,060–$1,200/mo	~$12,720–$14,400/yr	Lilly savings card available for commercially insured
Zepbound vials (Lilly direct)	~$349–$549/mo	~$4,200–$6,600/yr	Eli Lilly's cash-pay direct-to-consumer option
Compounded semaglutide (Trimi)	$99/mo	$1,188/yr	Same active ingredient; 503B pharmacy
Compounded tirzepatide (Trimi)	$125/mo	$1,500/yr	Same active ingredient; 503B pharmacy

Availability and Shortage Status (April 2026)

Supply shortages have been a persistent challenge for both Wegovy and Zepbound since their launches. Patient demand has consistently outpaced manufacturing capacity, leaving many patients unable to fill prescriptions or maintain their current dose.

Wegovy: Novo Nordisk has significantly expanded manufacturing since the 2022–2024 shortage crisis. As of early 2026, most dose strengths are more reliably available, though some regions still experience intermittent shortages of specific doses. The 2.4 mg maintenance dose is generally more available than it was in 2023.

Zepbound: Eli Lilly has also expanded tirzepatide manufacturing capacity. The introduction of single-dose vials (in addition to auto-injector pens) has helped improve overall supply. However, because Zepbound is newer and demand has been growing rapidly — including the January 2026 milestone of surpassing Ozempic in US search volume — certain doses continue to see tight supply in some markets.

Compounded alternatives: Compounded semaglutide and tirzepatide have maintained more consistent availability throughout the shortage period. Because production is distributed across multiple licensed compounding pharmacies rather than concentrated in a single manufacturer's facility, supply disruptions are less likely to create treatment interruptions. For patients who have experienced brand-name shortages, this is a meaningful advantage when considering the compounded tirzepatide program at Trimi.

Compounded Alternatives Save 90%

The Affordability Solution

For patients paying out of pocket, compounded semaglutide and tirzepatide through Trimi provide the same active ingredients at 90% less than brand-name pricing — with licensed provider oversight and accredited pharmacy partners.

Compounded Semaglutide

$99/month

vs ~$1,349/mo for brand Wegovy

Annual savings: ~$15,000

Compounded Tirzepatide

$125/month

vs ~$1,060–$1,200/mo for brand Zepbound

Annual savings: ~$11,000–$13,000

Compounded semaglutide and tirzepatide are legal, physician-prescribed medications prepared by licensed compounding pharmacies. They contain the same active pharmaceutical ingredient as Wegovy and Zepbound respectively — the molecule that does the work is identical. What differs is the manufacturing pathway and the cost structure.

Trimi partners with FDA-registered 503B outsourcing facilities and PCAB-accredited compounding pharmacies that perform third-party potency and sterility testing. Every patient receives a licensed medical provider review before prescription, ongoing provider access for dose adjustments, and comprehensive side effect management support. The entire process is designed around clinical outcomes, not just medication fulfillment.

For patients who want the weight loss outcomes of Zepbound but cannot afford $1,000+ per month, compounded tirzepatide at $125/month through Trimi delivers the same active molecule with medical supervision. For patients whose providers prefer semaglutide, compounded semaglutide at $99/month provides the Wegovy-equivalent molecule at a fraction of the cost. Learn more about how compounded tirzepatide compares to brand Zepbound in detail.

Which Should You Choose?

Choose Wegovy (or Compounded Semaglutide) If:

You have established cardiovascular disease and want the SELECT trial CV outcomes data behind your medication
You have had a good experience with semaglutide (e.g., on Ozempic for diabetes) and want to continue the same molecule
Your insurance covers Wegovy and your copay is reasonable
You want the longer-established track record and more published real-world safety data
Cost is a barrier and you want the most affordable compounded option ($99/mo at Trimi)

Choose Zepbound (or Compounded Tirzepatide) If:

You want the maximum average weight loss — clinical trials show tirzepatide superior to semaglutide by ~6 percentage points in head-to-head data
You have type 2 diabetes alongside obesity — Mounjaro (same molecule) has extensive diabetes data
You tried semaglutide and did not achieve adequate results or tolerate it well
Your insurance covers Zepbound and your copay is reasonable
You want access to the strongest obesity drug currently available and can access compounded tirzepatide ($125/mo at Trimi)

If you are starting treatment for the first time and cost is not a major barrier, many providers now lean toward tirzepatide (Zepbound or compounded) given the superior average weight loss data. However, individual response varies — some patients lose more weight on semaglutide than on tirzepatide, and there is no reliable way to predict which drug any given patient will respond to better without trying it.

For those primarily concerned with cost, compounded semaglutide at $99/month offers extraordinary value. For those who want to maximize their clinical odds of significant weight loss, compounded tirzepatide at $125/month delivers the statistically superior drug at an accessible price. Both are available through Trimi with licensed provider oversight.

Frequently Asked Questions

Which is better for weight loss, Wegovy or Zepbound?

Clinical trial data favors Zepbound (tirzepatide) for average weight loss. The SURMOUNT-1 trial showed 20.9% average weight loss with Zepbound at 15 mg, compared to 15-17% with Wegovy (semaglutide 2.4mg) in the STEP-1 trial. The head-to-head SURMOUNT-5 trial confirmed Zepbound produced significantly greater weight loss (20.2% vs 13.7%) over 72 weeks. However, individual responses vary considerably — some patients respond better to semaglutide than tirzepatide. The best drug is the one you can access, afford, and tolerate long-term.

Are Wegovy and Zepbound the same type of drug?

They are both injectable GLP-1 receptor agonists used for weight management, but they are not the same drug. Wegovy contains semaglutide, a single GLP-1 receptor agonist made by Novo Nordisk. Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. The dual-agonist mechanism of Zepbound is believed to account for its superior average weight loss outcomes in clinical trials.

What does Wegovy cost per month without insurance?

Wegovy lists at approximately $1,300–$1,500 per month without insurance. Novo Nordisk's savings card can reduce costs for eligible commercially insured patients, but Medicare and many state Medicaid plans do not cover Wegovy for weight loss. For patients paying out of pocket, compounded semaglutide through providers like Trimi starts at $99/month — the same active ingredient at roughly 90% less cost.

What does Zepbound cost per month without insurance?

Zepbound lists at approximately $1,060–$1,200 per month without insurance. Eli Lilly has introduced a direct-to-consumer vial option at a lower price point for cash-pay patients, typically $349–$549 per month depending on dose. Compounded tirzepatide through telehealth providers like Trimi starts at $125/month, representing savings of 85–90% compared to brand Zepbound.

Is Zepbound available or still in shortage in 2026?

Zepbound availability has improved significantly in 2026 following Eli Lilly's manufacturing expansion. However, specific dose strengths continue to experience intermittent shortages in certain regions. Compounded tirzepatide has maintained more consistent availability since it is produced by multiple independent compounding pharmacies rather than a single manufacturer. As of April 2026, both branded products have improved but variable supply.

Can I switch from Wegovy to Zepbound or vice versa?

Yes, with provider guidance. Switching between semaglutide and tirzepatide is possible but requires a brief washout or careful dose conversion since they are different molecules with different titration schedules. Most providers recommend restarting at a lower dose when switching to allow your body to adjust to the new medication. The transition is typically well-tolerated. Discuss the switch with your prescribing provider to determine the appropriate starting dose for the new medication.

Which has worse side effects, Wegovy or Zepbound?

Both share the same class of GI side effects — nausea, vomiting, diarrhea, constipation — because both work through the GLP-1 pathway. Clinical trials reported similar rates of GI adverse events for both drugs. Zepbound's additional GIP mechanism does not appear to substantially increase side effect burden compared to Wegovy. Nausea during dose escalation is the most common complaint for both. The side effect profiles are similar enough that individual tolerability varies more by person than by drug.

Get FDA-Equivalent Weight Loss Treatment at 90% Less

Trimi provides compounded semaglutide ($99/mo) and tirzepatide ($125/mo) — the same active ingredients as Wegovy and Zepbound — with licensed medical oversight, accredited pharmacy partners, and no surprise fees.

Start for $99/month Compare Treatments

Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Wegovy and Zepbound are FDA-approved prescription medications requiring evaluation by a licensed healthcare provider. Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies and require a prescription. Individual results vary. Do not start, stop, or change any medication without consulting your healthcare provider. Trimi is a telehealth platform that connects patients with licensed providers — it is not a pharmacy and does not dispense medications directly.

More on Weight Loss Medication Comparisons

Ozempic vs Mounjaro: The Diabetes Version Comparison

Tirzepatide vs Semaglutide 2026

Compounded Semaglutide vs Wegovy

Best GLP-1 Provider 2026